Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital isolated hyperinsulinism (CHI) is described in the packet's disease definition as a rare endocrine disease and as the most frequent cause of severe and persistent hypoglycemia in the neonatal period and early infancy. The definition characterizes it by excessive or uncontrolled insulin secretion, inappropriate for the level of glycemia. It also states that CHI comprises two forms: diazoxide-sensitive diffuse hyperinsulinism and diazoxide-resistant hyperinsulinism. The packet does not certify a prevalence estimate.
The packet lists no certified causative genes and no inheritance pattern for congenital isolated hyperinsulinism, so no gene-level or inheritance claim is made here. The packet lists the diazoxide-sensitive diffuse and diazoxide-resistant forms as subtypes, along with a familial hyperinsulinemic hypoglycemia entry.
The packet does not certify diagnostic methods or newborn screening information for this condition. It records an orphan drug designation for a fluorodopa F 18 agent as a diagnostic in the management of congenital hyperinsulinism; a designation is not an approval. Listed clinical studies also include fluorodopa PET imaging work aimed at detecting and localizing focal congenital hyperinsulinism.
The packet certifies no approved treatment records for congenital isolated hyperinsulinism, so coverage of approved options is unknown in this packet. The definition notes that hypoglycemic episodes require rapid and intensive treatment. The packet lists orphan drug designations for several investigational agents, including an insulin receptor antibody, glucagon analogs, and a pegylated glucagon receptor agonist. A designation is not an approval and does not establish that a product is in current development. No specialist or surveillance information is certified in this packet.
7 trials found
Prognosis is not certified in this packet.
The packet lists active clinical studies for this condition, including Phase 2 and Phase 3 studies of investigational agents (a glucagon analog and an insulin receptor antibody) and several studies of fluorodopa PET imaging. A patient organization listed in the packet is marked as maintaining a patient registry. Active clinical trials for this condition are listed on ClinicalTrials.gov.
Data assembled from 5 of 12 sources · Last updated Nov 18, 2026, 8:42 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center